Fox Chase Cancer Center

Site:	Fox Chase Cancer Center			Go to their website
Address:	333 Cottman Ave
City:	Philadelphia
State:	PA
Zip:	19111
Country:	USA

37 trials at this site

Phase	Trial [asc]	Trial Status	Site Status	Drug	NCT#
1	Phase 1 Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	Sunitinib + CP-751,871	NCT00729833
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
2	Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene	Completed	Closed	Crenolanib (CP-868,596)	NCT01243346
3	Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST	Active, not recruiting	Closed	Crenolanib (CP-868,596)	NCT02847429
2	Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01068769
3	Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg Imatinib)	Terminated	Closed	Sunitinib or Imatinib	NCT00372567
1	Safety Study of PLX108-01 in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 (PLX108-01)	NCT01004861
2	SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT06208748
1	Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)	Completed	Closed	Imatinib and Nilotinib	NCT00135005
3	Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients	Terminated	Closed	Imatinib	NCT01031628
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
2	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors	Active, not recruiting	Active, not recruiting	LOXO-101	NCT02576431
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
2	Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor	Active, not recruiting	Active	Temozolomide	NCT03556384
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
2	Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)	Terminated	Closed	Nilotinib and Imatinib	NCT01089595
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722